Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 4/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.30 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7058422 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2L3MBTL1CYP3A4TSHRTDP1 | |
| SCHEMBL7064754 | 0.73 | CA12 (0.45) | L3MBTL1TSHRTDP1MAPT | |
| SCHEMBL7064747 | 0.73 | CA12 (0.45) | L3MBTL1TSHRTDP1MAPT | |
| SCHEMBL7062412 | 0.69 | DPP4 (0.36) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5066904 | 0.68 | SMN1; SMN2 (0.38) | SMN1; SMN2L3MBTL1APEX1ACEDPP4 | |
| SCHEMBL7501140 | 0.68 | SMN1; SMN2 (0.38) | SMN1; SMN2L3MBTL1APEX1ACEDPP4 | |
| SCHEMBL385403 | 0.67 | ACE (0.59) | SMN1; SMN2L3MBTL1CYP3A4TSHRTDP1 | |
| SCHEMBL6141057 | 0.67 | ACE (0.59) | SMN1; SMN2L3MBTL1CYP3A4TSHRTDP1 | |
| SCHEMBL385463 | 0.67 | ACE (0.59) | SMN1; SMN2L3MBTL1CYP3A4TSHRTDP1 | |
| SCHEMBL7350501 | 0.65 | ACE (0.46) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0728746-B1 | Azepinone compounds useful in the inhibition of ACE and NEP | BRISTOL MYERS SQUIBB CO (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6143886-A | CYCLOPROPYL-SUBSTITUTED AZEPINONE COMPOUNDS WHICH ARE USEFUL EITHER AS SELECTIVE ANGIOTENSIN CONVERTING ENZYME INHIBITORS, OR AS DUAL INHIBITORS OF BOTH ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE | BRISTOL-MYERS SQUIBB CO. (US) | 2000-11-07 | — | — | US | disclosed |
| US-5994537-A | Process for preparing azepinone compounds useful in the inhibition of ACE and NEP | BRISTOL-MYERS SQUIBB CO. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5587375-A | TREATING BLOOD PRESSURE, INTRAOCULAR PRESSURE, CARDIOVASCULAR DISORDERS, GLAUCOMA, AND RENAL DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0728746-A1 | Azepinone compounds useful in the inhibition of ACE and NEP | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-28 | — | — | EP | disclosed |